Given your interest in Biotech, you might enjoy my recent piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme biocatalysis platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential. A multiple billion market potential as there's no current treatment for MASLD.
love this 👍
Hey Arye!
Given your interest in Biotech, you might enjoy my recent piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme biocatalysis platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential. A multiple billion market potential as there's no current treatment for MASLD.
https://www.slack-capital.com/p/exozymes-research-report